Overview

Safety, Tolerability and Pharmacokinetic Study of KL1333 in Healthy Male Volunteers

Status:
Completed
Trial end date:
2018-04-16
Target enrollment:
Participant gender:
Summary
The purpose of this First In Human study is to investigate the safety and tolerability of KL1333 after a single oral dose and to investigate the pharmacokinetic characteristics of KL1333 after a single oral dose.
Phase:
Phase 1
Details
Lead Sponsor:
Yungjin Pharm. Co., Ltd.